Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report.
Hanta
Ismail
I
Demir
Mesut
M
Akpinar
Onur
O
Kocabas
Ali
A
Ozbek
Suleyman
S
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008775:Methylprednisolone / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D017211:Treatment Failure; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D003520:Cyclophosphamide; D000068677:Sildenafil Citrate; D008775:Methylprednisolone